Journal article
Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis
Abstract
Herpes Simplex Virus 1 (HSV1) is amongst the most clinically advanced oncolytic virus platforms. However, efficient and sustained viral replication within tumours is limiting. Rapamycin can stimulate HSV1 replication in cancer cells, but active-site dual mTORC1 and mTORC2 (mammalian target of rapamycin complex 1 and 2) inhibitors (asTORi) were shown to suppress the virus in normal cells. Surprisingly, using the infected cell protein 0 …
Authors
Zakaria C; Sean P; Hoang H-D; Leroux L-P; Watson M; Workenhe ST; Hearnden J; Pearl D; Truong VT; Robichaud N
Journal
PLOS Pathogens, Vol. 14, No. 8,
Publisher
Public Library of Science (PLoS)
DOI
10.1371/journal.ppat.1007264
ISSN
1553-7366
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Adaptor Proteins, Signal TransducingAnimalsCatalytic DomainCell Cycle ProteinsCells, CulturedChlorocebus aethiopsEukaryotic Initiation Factor-4EGene Expression Regulation, NeoplasticHEK293 CellsHerpes SimplexHerpesvirus 1, HumanHumansImmediate-Early ProteinsMiceNeoplasmsOrganisms, Genetically ModifiedPhosphoproteinsProtein Kinase InhibitorsSignal TransductionTOR Serine-Threonine KinasesUbiquitin-Protein LigasesVero Cells